NCT06139367View on ClinicalTrials.gov

A Clinical Trial of TQB3454 Tablets in Healthy Adult Subjects

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 30, 2023

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Biliary Carcinoma
Interventions
DRUG

TQB3454 tablets

TQB3454 is a Isocitrate dehydrogenase 1 (IDH1) mutation inhibitor.

Trial Locations (1)

400010

The Affiliated Hospital of Qingdao University, Qingdao

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY